TGTX logo

TGTXTG Therapeutics Inc

$40.64
$4.00
(10.92%)
Today
Updated: 02:57 PM EDT
Reported EarningsMay 6
Mkt Cap$5.61B
Vol2.3M

About

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
399

Frequently Asked Questions

What is Market Cap of TG Therapeutics Inc?
What is the 52-week high for TG Therapeutics Inc?
What is the 52-week low for TG Therapeutics Inc?
What is TG Therapeutics Inc stock price today?
What was TG Therapeutics Inc stock price yesterday?
What is the PE ratio of TG Therapeutics Inc?
What is the Price-to-Book ratio of TG Therapeutics Inc?
What is the 50-day moving average of TG Therapeutics Inc?
How many employees does TG Therapeutics Inc have?